Genotoxic carcinogens are chemicals or factors which not only induce neoplastic lesions in animal bioassays but also test positive in genotoxicity assays in vitro or in vivo. However, it is actually di‹cult to discriminate genotoxic and non-genotoxic carcinogens because both assays are basically independent each other, which raises a simple query as to how much the detected genotoxic potential can consequently contribute to carcinogenicity. To clarify this critical issue, we have studied the mechanisms of action of carcinogens in transgenic rats or mice carrying reporter genes, which are expected as powerful tools for the simultaneous evaluation of both genotoxicity and carcinogenicity at the same organ level. A number of studies of genotoxic carcinogens using these transgenic rodents have revealed good correlations between genotoxicity and carcinogenicity in terms of mechanism of action. On the other hand, a known non-genotoxic carcinogen dicyclanil increased in vivo genotoxicity as well as oxidative DNA damage in female mice, consistently with the sex speciˆci-ty of its carcinogenicity, albeit without clear evidence of direct DNA reactivity. In contrast, a genotoxic chlorinated water by-product MX failed to exert in vivo genotoxicity and carcinogenicity in mice. We also conˆrmed that such reporter gene-carrying rodents are not susceptible or resistant to carcinogenicity as compared with intact counterparts. These results thus indicate that understanding of the detailed mechanism of carcinogenic action could be crucial for more precise risk assessment, and bioassay systems using transgenic rodents carrying reporter genes would be extremely useful for that purpose.
Introduction
Genotoxic carcinogens are chemicals or factors which not only induce neoplastic lesions in long-term animal bioassays but also test positive in genotoxicity assays in vitro or in vivo. In this context, test chemicals are classied into 4 categories, i.e., genotoxic carcinogens, nongenotoxic carcinogens, genotoxic non-carcinogens and non-genotoxic non-carcinogens. Based on this classiˆca-tion, genotoxic and non-genotoxic carcinogens are evaluated without and with thresholds in current risk assessment procedures, respectively (1) . However, it is actually di‹cult to discriminate genotoxic and non-genotoxic carcinogens because each assay is carried out separately. Namely, both assays are basically independent each other, which raises a simple query as to how much the detected genotoxic potential can contribute to carcinogenicity.
In this context, several possibilities are proposed for the critical issues that genotoxic carcinogens may also have the threshold. First, if a set of genotoxicity assays for a compound carcinogenic to rodents proved to be falsely positive, the compound is no more called as a genotoxic carcinogen, indicating the existence of true threshold as a non-genotoxic carcinogen. It may be di‹cult to conˆrm the genotoxic potential found in an assay as false positive, however, false reactions in a number of genotoxicity assays obviously exist judging from some discrepancy between in vitro and in vivo assays, as well as single dose and repeated dose in vivo studies. Second, it is unclear as to how much the detected genotoxicities contribute to the carcinogenicity found in long-term rodent assays. This point could be important to understand organ-, species-and sex-diŠerences of carcinogenicity. Third, it is well known that carcinogenesis process per se involves multi-steps such as DNA adduct formation/repair, gene mutation, apoptosis, cell proliferation and immune suppression. If there is a threshold in some of these steps, it is likely that the carcinogenic compound may have the threshold in inducing carcinogenicity. Even in the simplest hypothesis, both genotoxic and non-genotoxic or epigenetic events are required for the completion of carcinogenesis, suggesting a possible threshold determined with non-genotoxic events. Finally, statistical or mathematical approaches are concerned with possible practical thresholds even for true genotoxic carcinogens.
Taken together, it can be emphasized that the mechanisms of action are crucial to determine as to whether the initiation of carcinogenicity is based on the direct DNA reaction, how much the genotoxicity contributes to the carcinogenicity, or if the carcinogenicity alsoˆts to human risks. In this review article, our data using transgenic rodent mutation models/assays are shown, and the usefulness for investigating the mechanisms of carcinogenic action is discussed.
Transgenic Rodents Carrying Reporter Genes
Recently, a detailed review on several transgenic rodent mutation assays has been reported from OECD (2), in which Muta TM Mouse, Big Blue } , lacZ plasmid mouse, gpt delta rodents, use of the l cII transgene and other transgenic systems such as supF, lacI (BC-1), rpsL and bacteriophage FX174 are shown as promising models (2) . Among them, the gpt delta mouse was established by microinjection of lEG10 phage DNA (48 kb) into the fertilised eggs of C57BL/6J mice (3). Phage lEG10 carries about 80 copies of the transgene in a head-to-tail fashion at a single site of chromosome 17 and is maintained as a homozygote (i.e. the mouse carries about 160 copies of lEG10 DNA per diploid genome) (4). More recently, gpt delta rats have been developed in Sprague-Dawley (5) and F344 (6) backgrounds. The gpt delta rat has approximately 10 copies of the lEG10 vector integrated at position 4q24-q31. The transgenic rat is available as a hemizygote only (5). Mutation in the gpt delta mouse and rat can be assessed using 6-thioguanine and Spi -selection, which respond primarily to point mutation and deletion, respectively (7) .
To clarify the critical issues pointed out in the Introduction section, we have studied the mechanisms of action of carcinogens in transgenic rats or mice carrying reporter genes, which are expected to provide powerful tools for the evaluation of both genotoxicity and carcinogenicity at the same organ level.
Examples of Simultaneous Evaluation of Genotoxicity and Carcinogenicity in Transgenic Rodents
Our studies of genotoxic carcinogens such as environmental pollutants, nitrosamines and heterocyclic amines in these transgenic rodents have revealed good correlations between genotoxicity and carcinogenicity in terms of mechanism of action (6, 8, (10) (11) (12) (13) (14) (15) (16) .
In order to cast light on carcinogen-speciˆc molecular mechanisms underlying experimental hepatocarcinogenesis in rats, in vivo genotoxicity and mutation spectra of known genotoxic rat hepatocarcinogens Nnitrosopyrrolidine (NPYR), and 2-amino-3-methylimidazo[4,5-f]quinoline (IQ), as well as the non-genotoxic hepatocarcinogen di(2-ethylhexyl)phthalate (DEHP) and the non-carcinogen acetaminophen (APAP) were investigated in gpt delta transgenic rats (8) . After 13-week treatment, glutathione S-transferase placental form (GST-P)-positive liver cell foci were signiˆcantly increased in NPYR-and IQ-treated rats. In the DEHP-treated rats, marked hepatomegaly with centrilobular hypertrophy of hepatocytes occurred, although GST-P staining was consistently negative. There were no increases in GST-P positive foci in the APAP-treated rats. Positive genotoxicity was detected in IQ-and NPYR-treated rats of which mutant frequencies in the liver DNA were approximately 35-fold and 10-fold higher, respectively, than that of non-treatment control rats. There were no increases in mutant frequencies in the DEHP-or APAP-treated rats as compared to the non-treatment control value. IQ induced mainly base substitutions leading to G:C to T:A transversions and deletions of G:C base pairs. In contrast, NPYR primarily caused speciˆc AT to GC transitions, which are very rare in the other groups. These data provided support for the conclusion that hepatocarcinogenesis by IQ and NPYR depends on genotoxic processes and speciˆc DNA adduct formation while DEHP exerts its in‰uence via a non-genotoxic promotional pathway. Our data also indicate that analysis of speciˆc in vivo mutational responses with transgenic animal models can provide crucial information for understanding the molecular mechanisms underlying chemical carcinogenesis (8) . In fact, thymine adducts were detected at levels as much as guanine adducts in the liver of rats given NPYR (9) .
To clarify the role of 8-hydroxydeoxyguanosine (8-OHdG) formation as a starting point for carcinogenesis, we examined the dose-dependence and time-course of changes of OGG1 mRNA expression, 8-OHdG levels and in vivo mutations in the kidneys of gpt delta rats given KBrO3 in their drinking water for 13 weeks (6). There were no remarkable changes in OGG1 mRNA in spite of some increments being statistically signiˆcant. Increases of 8-OHdG occurred after 1 week at 500 ppm and after 13 weeks at 250 ppm. Elevation of Spi -mutant frequency suggestive of deletion mutations occurred after 9 weeks at 500 ppm although no mutations were increased before 5-weeks treatment (6) . In a twostage experiment, F344 rats were given KBrO3 for 13 weeks then, after a 2-week recovery, treated with 1z nitrilotriacetate (NTA), a known kidney tumorpromoter, in the diet for 39 weeks. The incidence and multiplicity of renal preneoplastic lesions in rats given KBrO3 at 500 ppm followed by NTA treatment were signiˆcantly higher than in rats treated with NTA alone. Results suggest that a certain period of time, more than 5 weeks in this experiment, might be required for 8-OHdG to cause permanent mutations. The two-step experiment shows that cells exposed to the alteration of the intranuclear status by oxidative stress including 8-OHdG formation might be able to form tumors with appropriate promotion (6) .
On the other hand, dicyclanil, a mouse hepatocarcinogen showing all negative results in various genotoxicity tests increased in vivo genotoxicity as well as oxidative DNA damage in mice (17) . Male and female gpt delta mice were given dicyclanil at a carcinogenic dose for 13 weeks. Signiˆcant increases in 8-OHdG levels and centrilobular hepatocyte hypertrophy were observed in the treated mice of both sexes. Bromodeoxyuridinelabeling indices and liver weights for the treated females, but not the males, were signiˆcantly higher than those for the controls. Likewise, the gpt mutant frequencies in the treated females were signiˆcantly elevated, GC:TA transversion mutations being predominant. The results for the transgenic mutation assays were consistent with dicyclanil carcinogenicity in terms of the sex speciˆcity for females although it still remains unclear how much sex hormone contributes to these sex diŠer-ences. Together with the early onset of 8-OHdG formation being observed 4 weeks after the treatment in the female B6C3F1 mice, a back strain of gpt delta mice, considering that 8-OHdG induces GC:TA transversion mutations by mispairing with A bases, it is likely that cells with high proliferation rates and a large amounts of 8-OHdG come to harbor mutations at high incidence. The results imply that examination of carcinogenic parameters concomitantly with reporter gene mutation assays is able to provide crucial information to comprehend the underlying mechanisms of so-called non-genotoxic carcinogenicity (17) .
It is well documented that a chlorinated water byproduct 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H )-furanone (MX) is strongly mutagenic in Ames assay without metabolic activation (18) and induces carcinogenicity targeting the liver, thyroid and lung in rats (19) . In contrast to dicyclanil, MX exerted neither in vivo genotoxicity nor carcinogenicity in mice (20) . Groups of male and female gpt delta transgenic mice were given MX at doses of 0-100 ppm in their drinking water for 12 weeks, and then killed to assess in vivo genotoxicity, and cell proliferative activity using immunohistochemistry for proliferating cell nuclear antigen (20) . Further groups of gpt delta mice were given 0 or 100 ppm MX for 78 weeks, and a full necropsy with histopathological examination of all organs was conducted to detect neoplastic lesions. The 12-week MX treatment did not result in genotoxicity in the livers or lungs or cell proliferative activity in several organs of the mice, and the 78-week treatment did not cause carcinogenicity. Theseˆndings indicate that MX is not genotoxic, mitogenic or carcinogenic in mice, and suggest that the compound might exert epigenetic actions for carcinogenicity in rats although its in vivo genotoxicity remains unknown in rats (20) .
Approaches for Genotoxic Carcinogens
Once a certain chemical was evaluated to be positive for both genotoxicity and carcinogenicity assays, the risk of such``genotoxic carcinogen'' is assessed on nonthreshold basis in the current risk assessment procedure. Based on properties of non-threshold, any genotoxic carcinogens are basically prohibited when intentionally added to food like food additives, or assessed with virtually safety dose (VSD) or margin of exposure (MOE) approaches when unavoidable from environment including food (1) . For``genotoxic carcinogens'', it may be critical to clarify the mechanism of action. As thê rst step, species speciˆcity could be determined from the weight of evidence (21, 22) . For example, a2u-globulin-related renal carcinogenicity in male rats is no more relevant to human risk (23) . If the mechanisms are more or less relevant to human risk, then contribution of genotoxicity to carcinogenicity should be evaluated. For this purpose, transgenic rodents carrying reporter genes would be very useful for judging direct, indirect or no DNA reactivity in vivo. Taken together with other mechanisms of action such as cell proliferation, apoptosis and immunodeˆciency, the key event for carcinogenicity would tell us as to whether there is any threshold. In some cases, other transgenic rodents such as p53, nrf2 or constitutive active/androstane receptor (CAR) knockout mice might be helpful to elucidate the mechanisms of action. Finally, statistical or mathematical evaluation can provide VSD or MOE even for strictly deˆned genotoxic carcinogens like radiation.
Conclusions
These results clearly indicate that understanding of the detailed mechanisms of carcinogenic action could be crucial for more precise risk assessment, and bioassay systems using transgenic rodents carrying reporter genes would be extremely useful for that purpose. We also conˆrmed that such reporter gene-carrying rodents are not susceptible or resistant to carcinogenicity (10, 14, 20) as compared with intact counterparts. Taken together, we propose a combined subchronic toxicity/in vivo genoxicity study using such transgenic rodents (Fig. 1) as a rapid and advanced bioassay to detect genotoxic carcinogens. In terms of additional approaches to detect in vivo genotoxic potential at organ levels, our proposing bioassay system may be more promising than a bioassay system extended from subchronic toxicity study suggested by Dr. Cohen (24) . 
